Chronic effect of oral cholestyramine, a bile salt sequestrant, and exogenous cholecystokinin on insulin release in rats

M. Kogire, Guillermo Gomez, T. Uchida, J. Ishizuka, G. H. Greeley, J. C. Thompson

Research output: Contribution to journalArticle

21 Citations (Scopus)

Abstract

Oral cholestyramine, a bile salt sequestrant, stimulates pancreatic exocrine secretion and growth chiefly by increasing cholecystokinin (CCK) release. In this report, we examine pancreatic insulin content and insulin release from the isolated perfused pancreas in rats given oral cholestyramine (4%, wt/wt) or subcutaneous CCK-8 (1 μg/kg every 8 h) for 2 weeks. Cholestyramine significantly increased pancreatic weight by 32%. CCK administration significantly increased pancreatic weight by 15%. Total pancreatic content of protein and DNA were also increased significantly by cholestyramine and pancreatic protein content was increased significantly by CCK administration. Total pancreatic insulin content was not affected by cholestyramine or CCK. Both cholestyramine and CCK significantly increased the first phase of glucose (8.4 mM)-stimulated release of insulin [mean insulin output (ng/min): control, 2.0 ± 0.1; cholestyramine, 2.7 ± 0.2; CCK, 2.6 ± 0.2]. Cholestyramine also significantly enhanced the second phase of glucose-stimulated release of insulin. Insulin release stimulated by CCK-8 (10-10 M) was not affected by oral cholestyramine or CCK treatment. These findings indicate that oral cholestyramine and exogenous CCK have a stimulatory effect on β cell function. Since pancreatic insulin content was not affected by cholestyramine and CCK treatment, cholestyramine and CCK may increase the sensitivity of β cells to glucose. The absence of a stimulatory effect of cholestyramine and CCK administration on insulin release in response to CCK-8 may be related to a down-regulation of CCK receptors on β cells.

Original languageEnglish (US)
Pages (from-to)15-20
Number of pages6
JournalPancreas
Volume7
Issue number1
StatePublished - 1992

Fingerprint

Cholestyramine Resin
Cholecystokinin
Bile Acids and Salts
Insulin
Glucose
Cholecystokinin Receptors
Weights and Measures

Keywords

  • Cholecystokinin
  • Cholestyramine
  • Glucose
  • Insulin
  • Isolated Perfused Pancreas
  • Rat

ASJC Scopus subject areas

  • Endocrinology
  • Gastroenterology

Cite this

Kogire, M., Gomez, G., Uchida, T., Ishizuka, J., Greeley, G. H., & Thompson, J. C. (1992). Chronic effect of oral cholestyramine, a bile salt sequestrant, and exogenous cholecystokinin on insulin release in rats. Pancreas, 7(1), 15-20.

Chronic effect of oral cholestyramine, a bile salt sequestrant, and exogenous cholecystokinin on insulin release in rats. / Kogire, M.; Gomez, Guillermo; Uchida, T.; Ishizuka, J.; Greeley, G. H.; Thompson, J. C.

In: Pancreas, Vol. 7, No. 1, 1992, p. 15-20.

Research output: Contribution to journalArticle

Kogire, M, Gomez, G, Uchida, T, Ishizuka, J, Greeley, GH & Thompson, JC 1992, 'Chronic effect of oral cholestyramine, a bile salt sequestrant, and exogenous cholecystokinin on insulin release in rats', Pancreas, vol. 7, no. 1, pp. 15-20.
Kogire M, Gomez G, Uchida T, Ishizuka J, Greeley GH, Thompson JC. Chronic effect of oral cholestyramine, a bile salt sequestrant, and exogenous cholecystokinin on insulin release in rats. Pancreas. 1992;7(1):15-20.
Kogire, M. ; Gomez, Guillermo ; Uchida, T. ; Ishizuka, J. ; Greeley, G. H. ; Thompson, J. C. / Chronic effect of oral cholestyramine, a bile salt sequestrant, and exogenous cholecystokinin on insulin release in rats. In: Pancreas. 1992 ; Vol. 7, No. 1. pp. 15-20.
@article{bf74e12d21ca4144a963ba8fbc351469,
title = "Chronic effect of oral cholestyramine, a bile salt sequestrant, and exogenous cholecystokinin on insulin release in rats",
abstract = "Oral cholestyramine, a bile salt sequestrant, stimulates pancreatic exocrine secretion and growth chiefly by increasing cholecystokinin (CCK) release. In this report, we examine pancreatic insulin content and insulin release from the isolated perfused pancreas in rats given oral cholestyramine (4{\%}, wt/wt) or subcutaneous CCK-8 (1 μg/kg every 8 h) for 2 weeks. Cholestyramine significantly increased pancreatic weight by 32{\%}. CCK administration significantly increased pancreatic weight by 15{\%}. Total pancreatic content of protein and DNA were also increased significantly by cholestyramine and pancreatic protein content was increased significantly by CCK administration. Total pancreatic insulin content was not affected by cholestyramine or CCK. Both cholestyramine and CCK significantly increased the first phase of glucose (8.4 mM)-stimulated release of insulin [mean insulin output (ng/min): control, 2.0 ± 0.1; cholestyramine, 2.7 ± 0.2; CCK, 2.6 ± 0.2]. Cholestyramine also significantly enhanced the second phase of glucose-stimulated release of insulin. Insulin release stimulated by CCK-8 (10-10 M) was not affected by oral cholestyramine or CCK treatment. These findings indicate that oral cholestyramine and exogenous CCK have a stimulatory effect on β cell function. Since pancreatic insulin content was not affected by cholestyramine and CCK treatment, cholestyramine and CCK may increase the sensitivity of β cells to glucose. The absence of a stimulatory effect of cholestyramine and CCK administration on insulin release in response to CCK-8 may be related to a down-regulation of CCK receptors on β cells.",
keywords = "Cholecystokinin, Cholestyramine, Glucose, Insulin, Isolated Perfused Pancreas, Rat",
author = "M. Kogire and Guillermo Gomez and T. Uchida and J. Ishizuka and Greeley, {G. H.} and Thompson, {J. C.}",
year = "1992",
language = "English (US)",
volume = "7",
pages = "15--20",
journal = "Pancreas",
issn = "0885-3177",
publisher = "Lippincott Williams and Wilkins",
number = "1",

}

TY - JOUR

T1 - Chronic effect of oral cholestyramine, a bile salt sequestrant, and exogenous cholecystokinin on insulin release in rats

AU - Kogire, M.

AU - Gomez, Guillermo

AU - Uchida, T.

AU - Ishizuka, J.

AU - Greeley, G. H.

AU - Thompson, J. C.

PY - 1992

Y1 - 1992

N2 - Oral cholestyramine, a bile salt sequestrant, stimulates pancreatic exocrine secretion and growth chiefly by increasing cholecystokinin (CCK) release. In this report, we examine pancreatic insulin content and insulin release from the isolated perfused pancreas in rats given oral cholestyramine (4%, wt/wt) or subcutaneous CCK-8 (1 μg/kg every 8 h) for 2 weeks. Cholestyramine significantly increased pancreatic weight by 32%. CCK administration significantly increased pancreatic weight by 15%. Total pancreatic content of protein and DNA were also increased significantly by cholestyramine and pancreatic protein content was increased significantly by CCK administration. Total pancreatic insulin content was not affected by cholestyramine or CCK. Both cholestyramine and CCK significantly increased the first phase of glucose (8.4 mM)-stimulated release of insulin [mean insulin output (ng/min): control, 2.0 ± 0.1; cholestyramine, 2.7 ± 0.2; CCK, 2.6 ± 0.2]. Cholestyramine also significantly enhanced the second phase of glucose-stimulated release of insulin. Insulin release stimulated by CCK-8 (10-10 M) was not affected by oral cholestyramine or CCK treatment. These findings indicate that oral cholestyramine and exogenous CCK have a stimulatory effect on β cell function. Since pancreatic insulin content was not affected by cholestyramine and CCK treatment, cholestyramine and CCK may increase the sensitivity of β cells to glucose. The absence of a stimulatory effect of cholestyramine and CCK administration on insulin release in response to CCK-8 may be related to a down-regulation of CCK receptors on β cells.

AB - Oral cholestyramine, a bile salt sequestrant, stimulates pancreatic exocrine secretion and growth chiefly by increasing cholecystokinin (CCK) release. In this report, we examine pancreatic insulin content and insulin release from the isolated perfused pancreas in rats given oral cholestyramine (4%, wt/wt) or subcutaneous CCK-8 (1 μg/kg every 8 h) for 2 weeks. Cholestyramine significantly increased pancreatic weight by 32%. CCK administration significantly increased pancreatic weight by 15%. Total pancreatic content of protein and DNA were also increased significantly by cholestyramine and pancreatic protein content was increased significantly by CCK administration. Total pancreatic insulin content was not affected by cholestyramine or CCK. Both cholestyramine and CCK significantly increased the first phase of glucose (8.4 mM)-stimulated release of insulin [mean insulin output (ng/min): control, 2.0 ± 0.1; cholestyramine, 2.7 ± 0.2; CCK, 2.6 ± 0.2]. Cholestyramine also significantly enhanced the second phase of glucose-stimulated release of insulin. Insulin release stimulated by CCK-8 (10-10 M) was not affected by oral cholestyramine or CCK treatment. These findings indicate that oral cholestyramine and exogenous CCK have a stimulatory effect on β cell function. Since pancreatic insulin content was not affected by cholestyramine and CCK treatment, cholestyramine and CCK may increase the sensitivity of β cells to glucose. The absence of a stimulatory effect of cholestyramine and CCK administration on insulin release in response to CCK-8 may be related to a down-regulation of CCK receptors on β cells.

KW - Cholecystokinin

KW - Cholestyramine

KW - Glucose

KW - Insulin

KW - Isolated Perfused Pancreas

KW - Rat

UR - http://www.scopus.com/inward/record.url?scp=0026569478&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0026569478&partnerID=8YFLogxK

M3 - Article

C2 - 1557341

AN - SCOPUS:0026569478

VL - 7

SP - 15

EP - 20

JO - Pancreas

JF - Pancreas

SN - 0885-3177

IS - 1

ER -